Dishman Carbogen Amcis Limited reported a strong fiscal year 2026, with total revenue reaching ₹29,319 million, an 8.1% year-over-year increase. The company saw robust growth in both its CDMO and Marketable Molecules segments. EBITDA margins expanded to 19.3% for the full year, driven by higher development revenue from late-stage projects and improved operational efficiencies in its specialty molecule supply chain, reflecting continued focus on high-value CDMO capabilities and strategic global growth.
Full Year Financial Performance
For the financial year ended March 31, 2026, the company achieved a total net revenue of ₹29,319 million, representing an 8.1% growth over the previous year. Profitability also showed significant improvement, with the annual EBITDA reaching ₹5,656 million, resulting in a margin expansion to 19.3%, compared to 17.3% in the prior year. This performance was underpinned by a disciplined approach to cost management and a focus on late-stage clinical projects.
Segmental Highlights
The company’s primary revenue driver, the CDMO segment, contributed ₹24,413 million to the annual revenue, reflecting a 6.5% year-over-year growth. This was primarily driven by revenue from late-stage Phase III molecules. Meanwhile, the Marketable Molecules segment demonstrated strong momentum, reporting revenue of ₹4,906 million, a significant 17.2% increase, largely due to higher supplies of Vitamin D analogues and improved operational cost parameters.
Strategic Growth and Outlook
Dishman continues to solidify its position as a preferred global outsourcing partner with a focus on high-value niche segments. The company currently manages a pipeline of 10 late-stage Phase III molecules and maintains a global workforce of over 2,200, including 950+ dedicated R&D scientists. With capital expenditure of CHF 22.4 million added during the year and successful GMP certifications across its global facilities, the company is well-positioned to meet the rising demand for oncology and specialized complex medicines through 2029.
Source: BSE
